Aptinyx Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • APTX
  • 1d3.11%
  • 1w3.11%
  • 1m47.69%
  • 1y-66.90%
ATH
  • ATH Price$31.85
  • ATH Date2018-09-10
  • % since ATH-99.70%
  • % to ATH33,077.08%
ATL
  • ATL Price$0.05
  • ATL Date2023-11-06
  • % from ATL92.00%
  • Last Low Price$0.05
  • Last Low Date2023-11-06
  • % From Last Low92.00%
IPO
  • IPO Price$17.40
  • % Current ROI USD-99.45%
  • ATH Price$31.85
  • % ROI ATH 6,370,000.00%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="APTX"]

Key Data [addtoany]

Current price $0.096
Sector Healthcare
Industry Biotechnology
Today's High/Low $0/$0
Volume 231,126.00
Previous Close $0.0931
52 Week High/Low $0.72/$0.031
Market Cap 6,500,707.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0
Annualized Dividend $0
$0.096
[addtoany]

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia.
It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment.
The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity